Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D.

Core Viewpoint - Verrica Pharmaceuticals has appointed Dr. Noah L. Rosenberg as Chief Medical Officer to enhance its drug development efforts, particularly for YCANTH® and other clinical-stage programs [2][8]. Company Overview - Verrica Pharmaceuticals is focused on developing medications for skin diseases requiring medical interventions, with its flagship product YCANTH® being the first FDA-approved treatment for molluscum contagiosum [8]. - The company is also working on treatments for common warts and has a licensing agreement with Lytix Biopharma AS for developing VP-315 for non-melanoma skin cancers [8]. Appointment of Chief Medical Officer - Dr. Noah L. Rosenberg brings over 30 years of experience in clinical and therapeutic development, having held senior positions in various biotechnology companies [2][8]. - His previous roles include Chief Medical Officer at Travere Therapeutics and Medimetriks Pharmaceuticals, where he led the development of significant products [2][8]. - The appointment is seen as a strategic move to advance Verrica's clinical programs and establish YCANTH® as a standard treatment for molluscum contagiosum [2][8]. Stock Option Grant - In connection with Dr. Rosenberg's appointment, he was granted a stock option award to purchase 325,000 shares of Verrica's common stock at an exercise price of $0.5221 per share [3][5]. - The stock option will vest over time, contingent on his continuous service with the company [5][6]. Product Information - YCANTH® is a proprietary drug-device combination product that effectively treats molluscum contagiosum, impacting approximately six million people in the U.S., primarily children [7][8]. - The product is available for$25 per treatment, with financial assistance options for patients in need [7].